Credit: Shutterstock
October 2, 2023 09:43 AM EDTUpdated 04:01 PM
Bioregnum

Q3 snap­shot: The IPO mar­ket shows fresh signs of im­prove­ment, but the biotech crunch con­tin­ues to bite

John Carroll

Editor & Founder

The biotech IPO mar­ket crashed hard last year, but we’re see­ing the win­dow creak open in a steady up­ward trend in 2023 that bodes for …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

A service from the Financial Times